10 minutes read

Pediatric oncology has been among China’s most rapidly advancing fields in the past 20 years — the National Children’s Medical Center dual-center system (Beijing Children’s Hospital + Shanghai Children’s Medical Center), together with Fudan Pediatric Hospital, has established a comprehensive pediatric oncology care network. 5-year overall survival for pediatric acute lymphoblastic leukemia has reached 91.1% (on par with international standards), and Renji Hospital’s pediatric liver transplant program has held the world’s #1 position for 10 consecutive years. For international pediatric patient families, China’s core value is: world-class clinical capability + haploidentical HSCT allowing parents to serve directly as donors + pricing approximately 1/10 of US costs + a documented record of successful international pediatric cases. This article walks through China’s pediatric oncology system, leading centers, capabilities by cancer type, pricing, and practical considerations for international families.

China’s Pediatric Oncology System

National Children’s Medical Center dual-center model [1]:

  • Beijing Children’s Hospital (Capital Medical University) — National Children’s Medical Center (Beijing)
  • Shanghai Children’s Medical Center (SCMC) (Shanghai Jiao Tong University School of Medicine) — National Children’s Medical Center (Shanghai)
  • Fudan University Pediatric Hospital — joined the National Children’s Medical Center management committee in 2023

National statistics [2]:

  • Approximately 40,000 new pediatric cancer cases per year
  • 2021–2022 nationwide 0–19 age group: 63,218 new cancer cases
  • Top three diagnoses: leukemia (30.68%), CNS tumors (18.41%), malignant epithelial tumors and melanoma (10.41%)
  • Cancer has become the second leading cause of death in Chinese children (after accidental injury)

5-year overall survival [3]:

  • 0–19 age group overall: 77.2% (2024 surveillance data 76.42%)
  • Retinoblastoma: 90.40%
  • Malignant epithelial tumors: 88.32%
  • Germ cell tumors: 86.37%

International comparison (honest disclosure):

  • US SEER data pediatric cancer 5-year survival rate >85%
  • Canada, Europe pediatric ALL reaches 90%
  • China’s overall figure trails by approximately 8–10 percentage points, but disease-specific outcomes approach or match international levels — pediatric ALL is a notable example (CCCG-ALL-2015 protocol 5-year OS 91.1%)

Practical implication for international families: China’s pediatric oncology has reached international levels for multiple specific cancers — especially ALL, liver tumors, neuroblastoma, pediatric brain tumors, and others. The overall survival gap largely reflects an averaging effect (limited by treatment resources in lower-tier cities), and leading National Children’s Medical Centers operate at levels on par with Western counterparts.

China’s Leading Pediatric Oncology Centers

Beijing Children’s Hospital (National Children’s Medical Center · Beijing) [4]

  • National Children’s Medical Center Beijing anchor
  • Treats approximately 300 pediatric leukemia cases annually (with another ~100 at the Baoding ward)
  • Has cured 3,500+ pediatric leukemia patients cumulatively as of 2022
  • CD19/GD2 CAR-T therapy for relapsed/refractory neuroblastoma in over 50 cases (see Article 26)
  • Overall capability ranked first nationally

Shanghai Children’s Medical Center (SCMC, National Children’s Medical Center · Shanghai) [5]

  • National Children’s Medical Center Shanghai anchor
  • International Diagnosis and Treatment Department
  • Specialties: neuroblastoma, retinoblastoma
  • Affiliated with Shanghai Jiao Tong University School of Medicine

Fudan University Pediatric Hospital [6]

  • National Children’s Medical Center member
  • In 2021, partnered with Fosun Pharma and Mevion to establish China’s first pediatric proton therapy center
  • Comprehensive pediatrics + pediatric oncology

Shanghai Renji Hospital Pediatric Liver Transplant Center (Academician Xia Qiang) [7]

  • Cumulative >3,200 pediatric liver transplants
  • 5-year survival 94%
  • World #1 for 10 consecutive years
  • Has completed 41+ international pediatric living donor liver transplants (see Article 23)

Beijing Tiantan Hospital Pediatric Neurosurgery [8]

  • Founded by Academician Wang Zhongcheng — China’s largest pediatric neurosurgery center
  • 1,000+ pediatric neurosurgeries annually
  • Includes 700+ pediatric intracranial tumors
  • Post-operative mortality <1‰

Guangzhou Women and Children Medical Center [9]

  • Annual pediatric leukemia diagnoses: 400–450
  • Solid tumors approximately 400
  • CNS tumors approximately 350
  • HSCT approximately 100 per year

Zhejiang University Children’s Hospital [10]

  • National Children’s Regional Medical Center
  • National Children’s Health and Disease Clinical Medical Research Center
  • Hematologic oncology as Zhejiang Province key academic discipline

Peking University People’s Hospital Bone and Soft Tissue Tumor Treatment Center

  • Pediatric bone and soft tissue sarcoma (see Articles 25 and 26)
  • Professor Guo Wei’s team with 3D-printed reconstruction

Capabilities by Cancer Type

1. Acute Lymphoblastic Leukemia (ALL) — International-Standard

CCCG-ALL-2015 protocol (modified from St Jude Total XV/XVI) [11]:

  • 5-year OS 91.1%
  • 5-year EFS 80.3%
  • CNS relapse rate 1.9%
  • Outcomes at international levels

Key feature: Beijing Children’s, SCMC, Fudan Pediatric, and multiple National Children’s Medical Centers use the unified protocol — outcomes comparable to St Jude (US), Great Ormond Street (UK), and other leading centers.

HSCT options: high-risk relapsed patients can receive haploidentical HSCT (Beijing Protocol, see Article 24) — allowing parents to serve directly as donors without bone marrow registry matching.

2. Acute Myeloid Leukemia (AML)

  • Standardized protocols at National Children’s Medical Centers
  • High-risk AML haploidentical HSCT mature
  • CAR-T for relapsed/refractory AML in clinical trials

3. Neuroblastoma — Beijing Children’s Hospital Leads

Beijing Children’s Hospital:

  • CD19/GD2 CAR-T therapy for relapsed/refractory neuroblastoma in over 50 cases [12]
  • Shenzhen GIMI 4SCAR-GD2 T cells in collaboration with Beijing multi-center clinical trial for high-risk NB
  • Effective on minimal residual disease in bone marrow

Practical implication for international families: relapsed/refractory neuroblastoma is one of the areas where China can deliver international-grade CAR-T treatment — while GD2 CAR-T in the US remains primarily in clinical trial settings.

4. Retinoblastoma — International-Standard Outcomes

Beijing Children’s Hospital + Tongren Hospital [13]:

  • Modern chemotherapy reduction + local treatment
  • Experienced centers achieve 5-year survival 90–95% — comparable to leading Western centers
  • Eye-preserving treatment capability mature

Shanghai Children’s Medical Center:

  • SCMC retinoblastoma specialty

5. Pediatric Brain Tumors — Beijing Tiantan is the Largest

Beijing Tiantan Hospital Pediatric Neurosurgery [8]:

  • 700+ pediatric intracranial tumor surgeries per year
  • Medulloblastoma approximately 200 cases/year
  • Brainstem tumors approximately 200 cases/year
  • Craniopharyngioma approximately 100 cases/year
  • Pineal region tumors approximately 100 cases/year
  • Post-operative mortality <1‰ (comparable to leading international pediatric neurosurgery centers)

6. Pediatric Liver Tumors — Renji Hospital Is World #1

Shanghai Renji Hospital Pediatric Liver Transplant Center [7]:

  • World’s largest pediatric liver transplant center
  • Cumulative >3,200 pediatric liver transplants
  • 5-year survival 94%
  • World #1 for 10 consecutive years
  • Indications: biliary atresia (most common), hepatoblastoma, metabolic liver diseases, and others

Beijing Tsinghua Changgung Hospital:

  • 100+ pediatric liver transplants per year
  • Perioperative survival approximately 97%
  • 1-year survival 89.3–95%

7. Pediatric Sarcoma — Peking University People’s 3D Printing

Peking University People’s Hospital Bone and Soft Tissue Tumor Treatment Center [14]:

  • Professor Guo Wei’s team
  • 3D-printed individualized pelvic prostheses (see Article 26)
  • Extensive limb-sparing surgery experience — avoiding functional loss from pediatric amputation

8. Pediatric Proton Therapy

Shanghai Proton and Heavy-Ion Center (SPHIC) [15]:

  • The only mature pediatric proton therapy option in China
  • Standard course 278,000 RMB (approximately $42,800 USD)
  • Indications: skull base tumors, pediatric brain tumors (especially medulloblastoma, ependymoma requiring avoidance of long-term side effects from conventional radiation), eye melanoma, etc.

Fudan Pediatric Hospital + Fosun Pharma + Mevion [6] — China’s first dedicated pediatric proton therapy center

  • Construction began in 2021
  • Progress ongoing

Core value of pediatric proton therapy: radiation dose only 1/40 of conventional radiation therapy (see Article 22) — for long-surviving pediatric patients, the value of avoiding late side effects (secondary tumors, cognitive development impact, endocrine dysfunction) is immeasurable.

Pricing Comparison: China vs the US (Pediatric Oncology)

[16]:

Treatment China All-Inclusive Cost (USD) US Cost
Pediatric ALL complete treatment cycle ~$23,000 (15万 RMB average) Evaluation $20K–$50K; treatment $200K–$400K
Pediatric AML complete treatment ~$34,000 (22万 RMB) $250K–$500K+
Low-risk ALL full course $15K–$31K $200K+
Pediatric liver transplant (family donor) See Article 23: ~$80K–$180K $500K+
Pediatric HSCT (haploidentical) See Article 24: ~$50K–$80K $300K+
Pediatric proton therapy ~$42,800 (SPHIC) $80K–$150K

Core comparison: Chinese pediatric oncology treatment costs approximately 1/10 of US — the most powerful economic case for international families paying out-of-pocket, with limited commercial insurance, or facing excessive home country wait times.

Practical Considerations for International Pediatric Families

Documented success cases:

Shanghai Renji Hospital Pediatric Liver Transplant [7]:

  • Southeast Asian patients account for 80% of liver transplant volume
  • Completed 41+ international pediatric living donor liver transplants
  • 40+ Malaysian patients
  • In 2019, Renji specialists traveled to University of Malaya Medical Centre to assist with Malaysia’s first two pediatric living donor liver transplants
  • Has treated pediatric patients from the Philippines, Indonesia, Mongolia, Malaysia, and other countries

Typical international pediatric patient scenarios:

  1. Pediatric liver transplant indications (biliary atresia, hepatoblastoma, Wilson disease, etc.) → Renji Hospital (see Article 23)
  2. Pediatric inherited blood disorders (thalassemia, SCID, etc.) requiring HSCT → Peking University People’s, Beijing Children’s, Nanfang Hospital (see Article 24)
  3. Relapsed/refractory ALL → Beijing Children’s / Zhejiang 1st CAR-T + haploidentical HSCT
  4. Neuroblastoma → Beijing Children’s CAR-T
  5. Pediatric brain tumors → Beijing Tiantan
  6. Pediatric sarcoma → Peking University People’s 3D printing
  7. Pediatric proton therapy indications → Shanghai SPHIC

Family accompaniment logistics:

  • Visa: at least one parent/primary caregiver applies for S1 visa (≥180 days, covering complete treatment cycle); other family on S2 visa
  • Accommodation: hotels or long-term rentals near the hospital; some hospitals (Renji, SCMC, Beijing Children’s) have partnered long-term apartments
  • Schooling for accompanying siblings: continue education at Chinese international schools or online schools — Shanghai, Beijing, and Guangzhou have many international school options; some major hospitals have temporary schools serving international patient families
  • Food: international cuisine is widely available in major Chinese cities, accommodating families from different cultural backgrounds

Typical total time in China:

Treatment Type Time in China
Pediatric ALL intensive treatment 6–9 months
Pediatric AML 6–12 months
Pediatric liver transplant 8–12 weeks
Pediatric HSCT 10–14 weeks
CAR-T 6–9 weeks
Pediatric proton therapy 6–10 weeks

Common Questions

My child is from country X — can China treat them? Major Chinese pediatric oncology centers commonly receive international pediatric patients — Renji Hospital’s 41+ international liver transplant cases are publicly documented evidence. The key for pre-evaluation is complete pathology + imaging + treatment history (see Article 7 on records preparation).

Is Chinese pediatric oncology really comparable to Western standards? Depends on the specific cancer:

  • ALL, HSCT, liver transplant, neuroblastoma CAR-T, retinoblastoma, brain tumors, sarcoma surgery: on par with leading Western centers
  • Overall average survival rate: China trails by 8-10 percentage points — this is an averaging effect; leading centers have reached international levels

Can parents accompany throughout? Absolutely yes, and strongly recommended (see Article 14 on family accompaniment). Chinese pediatric oncology culture assumes deep family involvement — parents can attend all consultations, participate in decisions, and provide bedside care during hospitalization.

What about education for accompanying siblings? Three main options:

  1. Short-term enrollment in Chinese international schools (extensive options in Beijing, Shanghai, Guangzhou)
  2. Home country online learning
  3. Temporary education services near the treating hospital

Can long-term follow-up after pediatric oncology treatment be done in the home country? Yes, and recommended. The critical step is establishing remote coordination between the Chinese primary physician and your home country pediatric oncologist. MedCareInChina facilitates this. Most pediatric cancers require 5–10 years of long-term follow-up (monitoring for recurrence and late side effects).

How does international insurance reimbursement work for pediatric oncology?

  • Most premium international medical insurance plans (MSH International, Cigna Global Plus, etc.) cover pediatric oncology treatment
  • The key is confirming the lifetime cap — long-term pediatric oncology costs can approach insurance caps
  • Some insurance has restrictions on “experimental therapies” like haploidentical HSCT and CAR-T — confirm before traveling

If the father serves as haploidentical HSCT donor, how much does it affect the father’s health? Haploidentical HSCT donor cells are primarily collected through peripheral blood apheresis (see Article 24) — no traditional bone marrow harvest surgery required. Donors typically recover normal activity within 1–2 weeks. Risk for parents serving as donors is approximately 0.2–0.5% — very low.

Bottom Line

Core value of pediatric oncology in China:

  • National Children’s Medical Center dual-center system (Beijing Children’s + SCMC + Fudan Pediatric)
  • Multiple specific cancers have reached international levels (ALL, liver transplant, neuroblastoma CAR-T, retinoblastoma, brain tumors)
  • Pricing approximately 1/10 of US — substantial economic significance for international families
  • Haploidentical HSCT allows parents to serve directly as donors — enabling transplant for children without matched donors
  • Accumulated international pediatric case experience (Renji 41+, Malaysian 40+, and other publicly documented cases)

Best-suited international pediatric oncology patients for travel to China:

  • Pediatric liver transplant indications (biliary atresia, hepatoblastoma, etc.)
  • Pediatric inherited blood disorders (thalassemia, SCID) requiring HSCT
  • Relapsed/refractory ALL or neuroblastoma requiring CAR-T
  • Pediatric brain tumors requiring complex neurosurgery + proton therapy
  • All pediatric oncology cases where home country treatment is unaffordable

If your child has cancer, MedCareInChina matches the most appropriate Chinese pediatric oncology center and team for the specific diagnosis — while assisting with family visas, accommodation, schooling for accompanying siblings, and coordination with the home country physician.

→ Send your case to hello@medcareinchina.com

See Service & Refund Policy and Medical Disclaimer for service boundaries.

Sources

  1. National Children’s Medical Center Dual-Center Model — Established January 2017 by NHC (then National Health and Family Planning Commission), anchored by Beijing Children’s Hospital and Shanghai Children’s Medical Center. Dual-center management committee established October 2023, adding Fudan University Pediatric Hospital. Source: https://wjw.beijing.gov.cn/xwzx_20031/jcdt/202310/t20231019_3282578.html
  2. China pediatric cancer annual incidence — Approximately 40,000 new cases per year. 2021-2022 nationwide 0-19 age group 63,218 new cases. Sources: China News Service https://www.bj.chinanews.com.cn/news/2024/0918/96413.html ; 2024 National Pediatric Oncology Surveillance Annual Report https://www.jkb.com.cn/news/industryNews/2026/0427/510524.html
  3. China pediatric cancer 5-year OS — 0-19 age 77.2%. Sources: CNR https://china.cnr.cn/gdgg/20251224/t20251224_527470739.shtml ; Ni Xin team Lancet report https://literature.chinacdc.cn/xuekefuwu/gonggongweishengxueshuredianzhuiz/202602/t20260205_314945.html
  4. Beijing Children’s Hospital — National Children’s Medical Center Beijing anchor.
  5. Shanghai Children’s Medical Center (SCMC) — National Children’s Medical Center Shanghai anchor.
  6. Fudan University Pediatric Hospital + China’s First Pediatric Proton Therapy Center — Built 2021 with Fosun Pharma + Mevion. Source: https://zh.wikipedia.org/wiki/%E5%A4%8D%E6%97%A6%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E5%84%BF%E7%A7%91%E5%8C%BB%E9%99%A2
  7. Shanghai Renji Hospital Pediatric Liver Transplant Center — Cumulative >3,200 cases, 5-year survival 94%, world #1 for 10 consecutive years; 41+ international pediatric patients; 40+ Malaysian cases. Sources: SJTU news https://news.sjtu.edu.cn/jdyw/20231130/191332.html ; CN-Healthcare https://www.cn-healthcare.com/articlewm/20230831/wap-content-1599366.html ; SJTU Medical School https://www.shsmu.edu.cn/ygc/info/1072/6291.htm
  8. Beijing Tiantan Hospital Pediatric Neurosurgery — Founded by Academician Wang Zhongcheng. 1,000+ pediatric neurosurgeries/year, 700+ intracranial tumors, post-op mortality <1‰. Sources: Brainmed https://www.brainmed.com/info/detail?id=24249 ; CCMU news https://news.ccmu.edu.cn/syyw_12977/100947.htm
  9. Guangzhou Women and Children Medical Center Hematology-Oncology — Annual leukemia 400-450, solid tumors 400, CNS 350, HSCT 100. Source: Sunflower Children https://www.curekids.cn/guidedetail/5240087ea3b545febbe4aa0ce7156573
  10. Zhejiang University Children’s Hospital — National Children’s Regional Medical Center + National Children’s Health and Disease Clinical Medical Research Center. Source: https://www.ncrcch.org.cn/content/details/id/9947
  11. CCCG-ALL-2015 Protocol — Chinese Children’s Cancer Cooperative Group protocol. 5-year OS 91.1%, EFS 80.3%, CNS relapse 1.9%. Source: PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC11562041/
  12. GD2 CAR-T Neuroblastoma — Shenzhen GIMI 4SCAR-GD2 + Beijing multi-center collaboration. Source: PharmCube https://bydrug.pharmcube.com/news/detail/542fdeb7c871dd8a17c78bbfdef65871
  13. Retinoblastoma Treatment — Beijing Children’s + Tongren Hospital. Experienced centers 5-year survival 90-95%. Source: CN-Healthcare https://www.cn-healthcare.com/articlewm/20240131/wap-content-1628694.html
  14. Peking University People’s Hospital Bone and Soft Tissue Tumor Treatment Center — Professor Guo Wei’s team with 3D-printed reconstruction. See Articles 25 and 26.
  15. Shanghai Proton and Heavy-Ion Center (SPHIC) Pediatric Treatment — Standard course 278,000 RMB (approximately $42,800 USD). See Article 22.
  16. China-US Pediatric Leukemia Cost Comparison — China ALL ~15万 RMB ≈ $23,000; AML ~22万 RMB ≈ $34,000. US treatment phase $200K-$400K. Source: Saint Lucia https://m.stluciabj.cn/news/gongsi/9503.html